 In June, 89bio Inc NASDAQ: ETNB announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia SHTG. SVB Leerink views these results as strong and says they provide a clear win for the company as. 